UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014525
Receipt number R000016880
Scientific Title A randomized, placebo-controlled study on efficacy and safety of combinational administration of mangosteen pericarps extracts and lychee fruit pericarps extracts in patients with metabolic syndrome
Date of disclosure of the study information 2014/07/31
Last modified on 2014/07/09 18:51:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized, placebo-controlled study on efficacy and safety of combinational administration of mangosteen pericarps extracts and lychee fruit pericarps extracts in patients with metabolic syndrome

Acronym

Efficacy and safety of the combinational administration of mangosteen pericarps extracts and lychee fruit pericarps extracts for metabolic syndrome

Scientific Title

A randomized, placebo-controlled study on efficacy and safety of combinational administration of mangosteen pericarps extracts and lychee fruit pericarps extracts in patients with metabolic syndrome

Scientific Title:Acronym

Efficacy and safety of the combinational administration of mangosteen pericarps extracts and lychee fruit pericarps extracts for metabolic syndrome

Region

Japan


Condition

Condition

Metabolic syndrome

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of the combinational administration of mangosteen pericarps extracts and lychee fruit pericarps extracts for metabolic syndrome

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visceral fat area, body weight(body mass index), abdominal circumstance, blood pressure, triglyceride, HDL-cholesterol, blood glucose

Key secondary outcomes

Subcutaneous fat area, total fat area, adiponectin, HMW adiponectin, leptin, adiponectin/ leptin, HMW adiponectin/ total adiponectin, HMW adiponectin/ leptin, questionnaire


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Ingestion of placebo capsules for 12 consecutive week

Interventions/Control_2

Ingestion of capsules include extract of pericarp of mangosteen and extract of lychee for 12 consecutive weeks

Interventions/Control_3

Ingestion of capsules include extract of pericarp of mangosteen for 12 consecutive weeks

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Japanese males and females between the ages of 35 and 65
2. abdominal circumference greater or equal 85cm in males and 90 cm in female on preliminary examination
3. applicable to more than two of three following indexes on preliminary examination; blood pressure greater or equal 130/85 mm Hg, triglycerides greater or equal 150mg/dL or serum high-density lipoprotein cholesterol (HDL-C) less 40 mg/dL, blood glucose greater or equal 110 mg/dL, body weight less100 kg, or body mass index greater or equal 25 kg/m2

Key exclusion criteria

1. having exercise or diets for reducing body weight
2. having the medicines or dietary supplements affecting body fat, serum triglyceride, or lipid metabolism potentially
3. having foods fortified with mangosteen or lychee extracts
4. with severe abnormalities of blood pressure or blood test
5. excessive habitual smoker or alcohol addict or extremely irregular food habits person
6. with severe disease receiving treatment
7. needing emergent treatment to diabetes, hepatopathy, renal or heart disease
8. having possibilities of emerging allergy related to the study
9. with pregnant (including with pregnant in plan), or in the lactation period
10. judged to be inadequate by the questionnaire of lifestyles
11. judged to be inadequate by biochemical assessment in blood on preliminary examination
12. taking part in other clinical trials within a month from the initiation of this clinical trial
13. judged to be inadequate by the doctors responsible for this clinical study.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sumio Kondo

Organization

Medical Corporation Kenshokai, Fukushima Healthcare Center

Division name

Director

Zip code


Address

2-12-16, Tamagawa, Fukushima-ku, Osaka 553-0004

TEL

06-6441-6848

Email

ko283434@ares.eonet.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Muneaki Iizuka

Organization

Total Technological Consultant Co., Ltd.(TTC)

Division name

Clinical Research Planning Dept.

Zip code


Address

1-20-2 Ebisu Nishi, Shibuya-ku, Tokyo 150-0021, Seibu Shinyokinko Ebisu Bldg

TEL

03-5459-5329

Homepage URL


Email

m.iizuka@ttc-tokyo.co.jp


Sponsor or person

Institute

Total Technological Consultant Co., Ltd.(TTC)

Institute

Department

Personal name



Funding Source

Organization

Lotte Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人健昌会 福島健康管理センター(Medical Corporation Kenshokai,Fukushima Healthcare Center)


Other administrative information

Date of disclosure of the study information

2014 Year 07 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 07 Month 17 Day

Date of IRB


Anticipated trial start date

2012 Year 08 Month 17 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2013 Year 04 Month 24 Day


Other

Other related information



Management information

Registered date

2014 Year 07 Month 09 Day

Last modified on

2014 Year 07 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016880


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name